Search Results 941-950 of 15327 for alt

1. S1406 A Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer - Mayo Clinic

   AST and ALT ≤ 2.5 x institutional upper limit of normal (IULN) or ≤ 5 x IULN if liver metastases are present within 14 days; Serum creatinine ≤ 1.5 x IULN ...

2. A Study To Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC - Mayo Clinic

   Alanine transaminase (ALT) ≤ 3 x ULN;; Serum amylase ≤ 2 x ULN or pancreatic amylase ≤ 1.5 x ULN. Subject must have adequate cardiovacular and respiratory ...

3. Early Feasibility Study To Evaluate The Safety And Recommended Dose Of The Sarah Nanotechnology System, For Patients With Stage 4 Metastatic Solid Tumors.The Investigational Device Uses Iron Oxide Nanoparticles Together With Non-Ionizing Alternating Magnetic Field To Generate Heat And Destroy Tumors - Mayo Clinic

   Leukocytes ≥3,000/mcL Absolute neutrophil count ≥1,500/mcL Platelets ≥100,000/mcL Total bilirubin ≤ 2.5 x limit of normal (ULN) AST(SGOT)/ALT(SGPT) ≤5 ...

4. Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) - Mayo Clinic

   Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤5 × ULN. Have adequate renal function as evidenced by: Serum creatinine <1.5 × ULN; OR ...

5. A Study to Determine the Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies - Mayo Clinic

   Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; for subjects with hepatic metastases, ALT and AST ≤ 5 × ULN;; Serum ...

6. A Study to Evaluate the Effectiveness of Acetazolamide to Treat Patients with Ataxia in PMM2-Congenital Disorder of Glycosylation - Mayo Clinic

   Participation eligibility · Hepatic impairment defined as AST/ALT > 5 x ULN in the last 12 months. · Renal impairment defined as serum creatinine 1.5-1.9 x ULN ...

7. Trastuzumab Emtansine in Treating Older Patients With Human Epidermal Growth Factor Receptor 2-Positive Stage I-III Breast Cancer - Mayo Clinic

   Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN); Alkaline phosphatase =< 2.5 x ULN; International ...

8. Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy - Mayo Clinic

   Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) ≤ 2.5x ULN; Alkaline Phosphatase <5x ULN. All females of childbearing potential (not ...

9. A Study to Evaluate Effectiveness and Safety of TD-1473 in Ulcerative Colitis - Mayo Clinic

   AST, ALT, or alkaline phosphatase ≥ 2 x the upper limit of normal (ULN);; Total bilirubin > 2 x ULN (unless diagnosis of Gilbert's syndrome);; Creatinine ...

10. Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer - Mayo Clinic

    In absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3.0 × ULN. If the patient has liver metastases, ALT and